Preventive Cardiovascular Care for Hypercholesterolemia in US Emergency Departments: A National Missed Opportunity.

Q3 Medicine Critical Pathways in Cardiology Pub Date : 2023-12-01 Epub Date: 2023-10-13 DOI:10.1097/HPC.0000000000000338
Nicklaus P Ashburn, Anna C Snavely, Rishi Rikhi, Michael D Shapiro, Michael A Chado, Jason P Stopyra, Simon A Mahler
{"title":"Preventive Cardiovascular Care for Hypercholesterolemia in US Emergency Departments: A National Missed Opportunity.","authors":"Nicklaus P Ashburn, Anna C Snavely, Rishi Rikhi, Michael D Shapiro, Michael A Chado, Jason P Stopyra, Simon A Mahler","doi":"10.1097/HPC.0000000000000338","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypercholesterolemia (HCL) affects nearly half of Emergency Department (ED) patients who present with possible acute coronary syndrome (ACS). However, it is unknown whether US ED providers obtain lipid panels, calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk, and prescribe cholesterol-lowering medications for these patients.</p><p><strong>Methods: </strong>We conducted a nationwide cross-sectional ED survey from April 18, 2023, to May 12, 2023. An electronic survey assessing current preventive HCL care practices for patients being evaluated for ACS. A convenience sample was obtained by sharing the survey with ED medical directors, chairs, and senior leaders using emergency medicine professional organization listservs and snowball sampling. Responding EDs were categorized as being associated with an academic medical center (AMC) or not (non-AMC).</p><p><strong>Results: </strong>During the 4-week study period, 110 EDs (50 AMC and 60 non-AMC EDs) across 39 states responded. Just 1.8% (2/110) stated that their providers obtain a lipid panel on at least half of patients with possible ACS and only one ED (0.9%) responded that its providers calculate 10-year ASCVD risk and prescribe cholesterol medication for the majority of eligible patients. Most reported never obtaining lipid panels (60.9%, 67/110), calculating 10-year ASCVD risk (55.5%, 61/110), or prescribing cholesterol-lowering medications (52.7%, 58/110).</p><p><strong>Conclusions: </strong>The vast majority of US ED providers do not provide preventive cardiovascular care for patients presenting with possible ACS. Most ED providers do not evaluate for HCL, calculate ASCVD risk, or prescribe cholesterol-lowering medications for these patients.</p>","PeriodicalId":35914,"journal":{"name":"Critical Pathways in Cardiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10843164/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Pathways in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/HPC.0000000000000338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hypercholesterolemia (HCL) affects nearly half of Emergency Department (ED) patients who present with possible acute coronary syndrome (ACS). However, it is unknown whether US ED providers obtain lipid panels, calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk, and prescribe cholesterol-lowering medications for these patients.

Methods: We conducted a nationwide cross-sectional ED survey from April 18, 2023, to May 12, 2023. An electronic survey assessing current preventive HCL care practices for patients being evaluated for ACS. A convenience sample was obtained by sharing the survey with ED medical directors, chairs, and senior leaders using emergency medicine professional organization listservs and snowball sampling. Responding EDs were categorized as being associated with an academic medical center (AMC) or not (non-AMC).

Results: During the 4-week study period, 110 EDs (50 AMC and 60 non-AMC EDs) across 39 states responded. Just 1.8% (2/110) stated that their providers obtain a lipid panel on at least half of patients with possible ACS and only one ED (0.9%) responded that its providers calculate 10-year ASCVD risk and prescribe cholesterol medication for the majority of eligible patients. Most reported never obtaining lipid panels (60.9%, 67/110), calculating 10-year ASCVD risk (55.5%, 61/110), or prescribing cholesterol-lowering medications (52.7%, 58/110).

Conclusions: The vast majority of US ED providers do not provide preventive cardiovascular care for patients presenting with possible ACS. Most ED providers do not evaluate for HCL, calculate ASCVD risk, or prescribe cholesterol-lowering medications for these patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
美国急诊科高胆固醇血症的预防性心血管护理:一个全国性错失的机会。
背景:高胆固醇血症(HCL)影响了近一半可能出现急性冠状动脉综合征(ACS)的急诊科(ED)患者。然而,尚不清楚美国ED提供者是否获得脂质小组,计算10年动脉粥样硬化性心血管疾病(ASCVD)的风险,并为这些患者开降胆固醇药物。方法:我们于2023-12-12/2023年4月18日在全国范围内进行了一项ED横断面调查。一项评估ACS患者当前预防性HCL护理实践的电子调查。通过使用急诊医学专业组织listservs和雪球抽样与ED医疗主管、主席和高级领导分享调查,获得了一个方便的样本。有反应的ED被归类为与学术医疗中心(AMC)或非学术医疗中心相关。结果:在为期四周的研究期间,39个州的110名ED(50名AMC和60名非AMC ED)做出了反应。只有1.8%(2/110)的人表示,他们的提供者获得了至少一半可能患有ACS的患者的脂质小组,只有一名ED(0.9%)回应说,其提供者计算了10年ASCVD风险,并为大多数符合条件的患者开了胆固醇药物。大多数报告称从未获得脂质组(60.9%,67/110),计算10年ASCVD风险(55.5%,61/110),或开具降胆固醇药物(52.7%,58/110)。结论:绝大多数美国ED提供者没有为可能出现ACS的患者提供预防性心血管护理。大多数ED提供者不评估HCL,不计算ASCVD风险,也不为这些患者开降低胆固醇的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Critical Pathways in Cardiology
Critical Pathways in Cardiology Medicine-Medicine (all)
CiteScore
1.90
自引率
0.00%
发文量
52
期刊介绍: Critical Pathways in Cardiology provides a single source for the diagnostic and therapeutic protocols in use at hospitals worldwide for patients with cardiac disorders. The Journal presents critical pathways for specific diagnoses—complete with evidence-based rationales—and also publishes studies of these protocols" effectiveness.
期刊最新文献
Altered anthropometrics and HA1c levels, but not dyslipidemia, are associated with elevated hs-CRP levels in middle-aged adults: A population-based analysis. Role of Embolic Protection in Percutaneous Coronary Intervention without Saphenous Venous graft lesions in ST-elevation myocardial infarction - a systematic review and meta-analysis. Temporal Trends and Outcomes of Peripheral Artery Disease and Critical Limb Ischemia in the United States. Emergency Department and Critical Care Use of Clevidipine for Treatment of Hypertension in Patients with Acute Stroke. Impact of as Needed Heparin Boluses on Supratherapeutic Activated Partial Thromboplastin Time in Patients Managed With Extracorporeal Membrane Oxygenation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1